Q32 Bio (NASDAQ:QTTB) Stock Rating Lowered by Wall Street Zen

Q32 Bio (NASDAQ:QTTB) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Q32 Bio in a research report on Tuesday. Two analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $12.17.

Q32 Bio Price Performance

Shares of QTTB stock opened at $3.17 on Friday. The company has a market capitalization of $38.67 million, a price-to-earnings ratio of -0.74 and a beta of 0.11. Q32 Bio has a one year low of $1.35 and a one year high of $53.17. The company’s fifty day moving average price is $2.13 and its 200-day moving average price is $1.92.

Q32 Bio (NASDAQ:QTTB) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($0.78) EPS for the quarter, beating the consensus estimate of ($1.14) by $0.36. Equities research analysts expect that Q32 Bio will post -12.32 earnings per share for the current fiscal year.

Institutional Trading of Q32 Bio

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Monaco Asset Management SAM increased its holdings in Q32 Bio by 17.1% in the 2nd quarter. Monaco Asset Management SAM now owns 591,937 shares of the company’s stock valued at $882,000 after acquiring an additional 86,486 shares during the last quarter. Nuveen LLC bought a new stake in shares of Q32 Bio in the 1st quarter worth about $92,000. Jane Street Group LLC bought a new stake in shares of Q32 Bio in the 2nd quarter worth about $69,000. Goldman Sachs Group Inc. increased its holdings in shares of Q32 Bio by 140.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 44,373 shares of the company’s stock worth $73,000 after buying an additional 25,953 shares during the last quarter. Finally, AQR Capital Management LLC bought a new stake in shares of Q32 Bio in the 1st quarter worth about $68,000. 31.32% of the stock is currently owned by institutional investors.

Q32 Bio Company Profile

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.